Short answer
Axogen, Inc. (AXGN) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.3 (Exhibit EX-99.3). Axogen announced third-quarter 2026 financial results on October 28, 2026.
Axogen, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Axogen announced third-quarter 2026 financial results on October 28, 2026
- Full financial results and management commentary are contained in Exhibit 99.1, the accompanying earnings release
Item 7.01 · Regulation FD Disclosure
- Q3 2026 financial results presentation posted October 28, 2026, providing investor-facing performance information
- Updated corporate presentation posted October 28, 2026, signaling refreshed company strategy and business overview
- Presentations available for analyst and investor discussions through Axogen’s investor-relations website
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $75.8M, up 26.2% YoY, with broad-based growth across major markets
- Adjusted EBITDA $13.4M, up from $9.2M, while gross margin declined to 74.8% from 76.6%
- 2026 revenue guidance raised to at least $290M, representing at least 29% growth, including $7M from BioCircuit
- $225M net offering proceeds funded the $200M BioCircuit acquisition, creating substantial shareholder dilution
- Cash, restricted cash and investments reached $350.1M, while debt was eliminated by September 30, 2026
Item EX-99.2 · Exhibit EX-99.2
- Q3 revenue $75.8M, up 26.2% YoY, extending strong growth across Axogen’s nerve-care markets
- Adjusted EBITDA $13.4M, margin 17.7% versus 15.4%, signaling operating leverage despite expanded commercial investment
- Cash, equivalents, restricted cash and investments $350.1M with no debt obligations, supporting further sales and product-development spending
- Full-year guidance: revenue growth at least 29% to $290M, organic growth at least 26% to $283M, gross margin at least 73%
- Prostate program reached 220+ procedures across 15 clinical sites, with detailed outcomes scheduled for November 9, 2026
Item EX-99.3 · Exhibit EX-99.3
- Corporate presentation outlines a $5.6B U.S. nerve-care opportunity, with minimal current penetration and more than 1.5M annual injuries in focus markets
- 2026 guidance: revenue growth at least 29% to $290M, organic growth at least 26% to $283M, gross margin at least 73%, positive free cash flow
- Commercial expansion targets extremities, breast, oral/maxillofacial and head-and-neck, plus prostate applications with projected 15%-20% CAGR
- Avance coverage expanded to 87.6M additional lives since Q2 2025, supporting reimbursement-driven adoption
- Key execution risks: clinical outcomes, regulatory approvals, surgeon adoption, reimbursement, supply chain pressures and hospital staffing challenges
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Axogen, Inc. 8-K filings
Get the next AXGN 8-K as it lands
Follow AXGN for push alerts, or ask the research agent what this filing means.